ROCKVILLE, Md., Dec. 7, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the microbiome while
targeting pathogen-specific diseases, announced that its Microbiome
Clinical Program Seminar will be webcast live at 9:00 a.m. EST on Thursday,
December 10, 2015.
The Seminar will provide clinical updates on Synthetic
Biologics' gut microbiome candidates – SYN-010 and SYN-004:
SYN-010 – Treatment of irritable bowel syndrome
with constipation (IBS-C)
Topics: First and second Phase 2 clinical trials
Presenters:
- Mark Pimentel, MD, FRCP(C),
Director, GI Motility Program, Professor of Medicine, Cedars-Sinai,
Los Angeles, CA
- Marianela de la Portilla, MD,
Principal Investigator, Genoma Research Group, Miami, FL
SYN-004 – Prevention of C. difficile
infection (CDI) and antibiotic-associated diarrhea (AAD)
Topics: Phase 1a and 1b, first and second Phase 2a and
Phase 2b clinical trials
Presenters:
- Professor Mark H. Wilcox, MD,
FRCPath, Consultant / Head of Microbiology, Leeds Teaching
Hospitals NHS Trust, Professor of Medical Microbiology, University
of Leeds, Lead on C. difficile Infection, Public Health
England
- Eric Sicard, MD, Principal
Investigator, Algorithme Pharma, Quebec,
Canada
A live webcast of the presentations will begin on December 10, 2015 at 9:00
a.m. EST and is scheduled to conclude by 11:30 a.m. EST. The live webcast of the event
will be available via the internet at: http://bit.ly/1QWBpYN. The
archived webcast will be available at the same URL,
http://bit.ly/1QWBpYN, for at least 90 days following the
Seminar.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development include: (1) SYN-004 which is designed to
protect the gut microbiome from the effects of certain commonly
used intravenous (IV) antibiotics for the prevention of C.
difficile infection (CDI) and antibiotic-associated diarrhea
(AAD), and (2) SYN-010 which is intended to reduce the impact of
methane producing organisms in the gut microbiome to treat an
underlying cause of irritable bowel syndrome with constipation
(IBS-C). In addition, the Company is developing a Phase 2 oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS, and in
collaboration with Intrexon Corporation (NYSE: XON), a preclinical
stage monoclonal antibody for the prevention and treatment of
Pertussis and discovery stage biotherapeutics for the treatment of
phenylketonuria (PKU). For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-webcast-microbiome-clinical-program-seminar-300188636.html
SOURCE Synthetic Biologics, Inc.